Search Results
Oct 20, 2025, 09:31 ET Facultad de Yale reconocida con prestigiosos honores nacionales por sus logros en salud y medicina
cómo los cánceres evaden la detección inmune. Chen descubrió la molécula PD-L1, una proteína expresada en las células cancerosas que suprime la respuesta inmune y promueve el crecimiento tumoral. Su trabajo también reveló que PD-L1 está altamente regulado al alza en algunos cánceres y que dirigirse a la
More news about: Yale School of Medicine
Oct 20, 2025, 09:00 ET Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device
/CNW/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company focused on revolutionizing women's health, is pleased to announce that it has commenced prototype
More news about: Zero Candida
Oct 20, 2025, 09:00 ET Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device
/PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company focused on revolutionizing women's health, is pleased to announce that it has commenced prototype
More news about: Zero Candida
Oct 20, 2025, 09:00 ET Ownership Works Launches First International Affiliate in Japan, Marking the Start of a Global Shared Ownership Movement
Japan Growth Investments Alliance (JGIA) Japan Industrial Partners KKR L Catterton Nippon Investment Company (NIC) Polaris Capital Group Warburg
More news about: Ownership Works
Oct 20, 2025, 08:50 ET Park River Holdings, Inc. Announces Expiration and Final Results of Exchange Offers for Outstanding 5.625% Senior Notes due 2029 and 6.750% Senior Notes due 2029 and Consent Solicitations
70082L AA5 / US70082LAA52 U7024L AA5 / USU7024LAA53
More news about: PrimeSource Brands
Oct 20, 2025, 08:47 ET L-Nutra Recognized by Shortlister as a Q4 Top Vendor in Both Corporate Weight Management and Diabetes Management Programs
Growth at L-Nutra. "Employers today don't just want another wellness perk - they want solutions that are clinically validated, trackable, and proven to work. Most other solutions are too superficial. Our programs deliver measurable outcomes that are sustained over time." The L-Nutra
More news about: L-Nutra Inc.
Oct 20, 2025, 08:36 ET Survivor of 1,775 Days of Unjust Detention in Venezuela Shares His Story
dollars, being CIA employees, and collaborating with the US Government to impose economic sanctions on Venezuela and some of its top officials. Jorge L. Toledo, a Venezuelan-born American citizen and former CITGO executive is sharing his story about his wrongful detention for almost five years, and the
More news about: Archway Publishing
Oct 20, 2025, 08:00 ET The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression
redestrant-in-reducing-tumor-proliferation-in-erher2--breast-cancer-at-early-stages-without-the-need-for-ovarian-function-suppression-302588871.html SOURCE MEDSIR
More news about: MEDSIR
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
on file: ABVRRTI 81918 RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.; 2025. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken).
More news about: AbbVie
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs
More news about: HanchorBio Inc.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
presented at ObesityWeek® 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Poster 711. Busetto L, Contreras CO, Christensen MH, et al. CagriSema and achievement of BMI and waist-to-height ratio treatment targets: REDEFINE 1. Poster presentation presented
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
presented at ObesityWeek® 2025; 4-7 November 2025; Georgia World Congress Center, Atlanta, GA, US. Poster 711. Busetto L, Contreras CO, Christensen MH, et al. CagriSema and achievement of BMI and waist-to-height ratio treatment targets: REDEFINE 1. Poster presentation presented
More news about: NOVO NORDISK INC.
Oct 20, 2025, 06:00 ET IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
approximately 12 months (ES Rantala et al, Melanoma Research, 2019; L Khoja et al, Annals of Oncology, 2019). IDEAYA is conducting a registration-enabling Phase 2/3 trial (OptimUM-02) of the darovasertib and crizotinib combination in 1L HLA*A2:01-negative mUM and is targeting to report median PFS data
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 03:52 ET Geely Deploys Raytron's Automotive Thermal Camera on LEVC L380 to Reduce Night Collisions
a inherent hazard on the road. According to the NHTSA, the traffic fatality rate is three times higher at night than during the day. The Geely LEVC L380, a premium electric MPV, tackles the risk with a suite of 28 perception sensors. At the heart of its predictive safety is an advanced Infrared Night
More news about: Raytron Technology Co., Ltd.
Oct 20, 2025, 03:46 ET Huawei Luncurkan Solusi AI WAN dengan Arsitektur "AI-Centric" yang Mendorong Pertumbuhan Bisnis Operator Telekomunikasi
dari 45 menit menjadi hanya 5 menit berkat basis data yang mencakup 300.000 kasus. Sementara, MasOrange Spanyol menerapkan jaringan otonom IP Level 4 (L4 Autonomous Driving Network) berbasiskan AI WAN Huawei yang mempersingkat rata-rata perbaikan jaringan, memangkas biaya, dan meningkatkan efisiensi.
More news about: Huawei
Oct 20, 2025, 02:20 ET Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
adebrelimab in the gastrointestinal field were featured. In addition, investigational agents including HRS-4642 (a KRAS G12D inhibitor) and SHR-1701 (a PD-L1/TGF-β bifunctional antibody) were also presented, reflecting the strong momentum of both Hengrui's established portfolio and emerging pipeline in advancing
More news about: Hengrui Pharma
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). Antengene
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
combination therapy cohorts (E-H), CS5001 will be administered with standard systemic therapies (R-GemOx, R2 or R-CHOP) or with sugemalimab (an anti-PD-L1 monoclonal antibody). Patient enrollment for CS5001 Phase Ib study commenced in December 2024 and is currently advancing
More news about: CStone Pharmaceuticals
Oct 19, 2025, 19:26 ET Maratón Híbrida de Diez Países: Omoda | Jaecoo Lideran su Segmento
Alemania – 1,159 km, Italia – 1,161 km, EAU – 1,192 km; 4.8L/100km. Jaecoo 5 SHS-H: Malasia – 890 km, Australia & Nueva Zelanda – 827 km, Tailandia – 857 km; 4.3L–5.0L/100km. Omoda
More news about: Chirey Motors
Oct 19, 2025, 19:02 ET OMODA | JAECOO presentan su poder tecnológico en la International Technology Night
Super Hybrid, que ofrece alto desempeño, autonomía extendida y bajo consumo, con una eficiencia de 44,5% y un consumo combinado de 5,99 L/100 km. Su batería híbrida garantiza seguridad, autonomía eléctrica de 90 km y salida de energía externa de 3,3 kW, ideal para experiencias
More news about: Chirey Motors
Oct 19, 2025, 11:42 ET Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
In the COMPASSION-15 study, patients with PD-L1 CPS <5 (low expression) and CPS <1 (negative expression) are 49.8% and 23%, respectively, of the ITT population. This represents a higher proportion of PD-L1 low and negative patient population in COMPASSION-15 compared to previous
More news about: Akeso, Inc.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Consistent clinical benefits were observed across all PD-L1 expression subgroups. In the PD-L1 negative (TPS <1%) population, the PFS HR was 0.55 for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy. In the PD-L1 positive (TPS ≥1%) population, the PFS HR was 0.66 for ivonescimab
More news about: Akeso, Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
deletions or exon 21 L858R mutations.15†‡ Amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a Category 1 recommendation for patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations who experienced
More news about: Johnson & Johnson
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
recurrent or metastatic NPC patients who had progressed after at least two prior lines of chemotherapy, including platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. These results were presented today in a late-breaking oral presentation at the 2025 European Society of Medical Oncology (ESMO) Congress.
More news about: SystImmune, Inc.
Oct 19, 2025, 07:32 ET 穿越都市與山野，LEPAS環球優雅駕控之旅全路況解鎖優雅出行
在上海市區路段，嘉賓重點體驗了城市油路和車輛起步加速，LEPAS L8平順的起步加速、寬敞的車內空間、舒適的座椅獲得了肯定，在音響系統的悠揚旋律中，詮釋了都市的摩登優雅。在駛往蘇州的高速路段，ACC自適應巡航等駕駛輔助功能全程護航，園林的清新與智能科技相得益彰。 在莫干山盤山公路上，LEPAS L8 精準的動力響應與轉向調校，從容應對複雜路況。在莫干山露營基地，車輛外放電功能為營地供電，車頂燈組點亮夜空，營造出溫暖而高級的戶外生活場景，試駕嘉賓在此圍坐交流，感受遠山的靜謐與自然之美，體驗優雅生活方式。
More news about: 奇瑞集團